Bristol Myers Squibb Company $BMY Position Cut by Keybank National Association OH

Keybank National Association OH decreased its position in Bristol Myers Squibb Company (NYSE:BMY) by 1.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 492,372 shares of the biopharmaceutical company’s stock after selling 8,259 shares during the period. Keybank National Association OH’s holdings in Bristol Myers Squibb were worth $30,724,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. BlackRock Inc. grew its position in shares of Bristol Myers Squibb by 5.1% during the 2nd quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock worth $10,393,783,000 after buying an additional 8,702,106 shares during the period. State Street Corp raised its stake in shares of Bristol Myers Squibb by 7.3% during the second quarter. State Street Corp now owns 105,757,638 shares of the biopharmaceutical company’s stock worth $6,093,755,000 after buying an additional 7,192,724 shares during the last quarter. Primecap Management Co. CA bought a new stake in shares of Bristol Myers Squibb during the second quarter worth approximately $1,436,115,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Bristol Myers Squibb by 0.5% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 22,839,010 shares of the biopharmaceutical company’s stock valued at $1,315,984,000 after buying an additional 119,690 shares during the period. Finally, Dimensional Fund Advisors LP lifted its holdings in Bristol Myers Squibb by 2.9% in the first quarter. Dimensional Fund Advisors LP now owns 18,762,589 shares of the biopharmaceutical company’s stock valued at $1,137,847,000 after buying an additional 520,330 shares during the period. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, SVP Phil M. Holzer sold 500 shares of Bristol Myers Squibb stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the transaction, the senior vice president owned 16,862 shares in the company, valued at $1,138,185. The trade was a 2.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Julia A. Haller sold 3,800 shares of Bristol Myers Squibb stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $63.31, for a total value of $240,578.00. Following the transaction, the director owned 30,279 shares in the company, valued at $1,916,963.49. This trade represents a 11.15% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.05% of the stock is owned by corporate insiders.

Bristol Myers Squibb Trading Up 0.2%

Shares of NYSE BMY opened at $62.91 on Thursday. The company’s fifty day moving average is $62.09 and its 200-day moving average is $60.23. The stock has a market cap of $128.59 billion, a price-to-earnings ratio of 10.08, a P/E/G ratio of 0.32 and a beta of 0.20. Bristol Myers Squibb Company has a twelve month low of $45.26 and a twelve month high of $68.64. The company has a quick ratio of 1.44, a current ratio of 1.59 and a debt-to-equity ratio of 1.79.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.10 by $0.25. Bristol Myers Squibb had a net margin of 18.47% and a return on equity of 60.48%. The company had revenue of $13.07 billion during the quarter, compared to analyst estimates of $12.72 billion. During the same quarter in the previous year, the business earned $1.63 EPS. The firm’s revenue was up 6.9% on a year-over-year basis. Equities research analysts predict that Bristol Myers Squibb Company will post 6.45 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd were paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 4.0%. The ex-dividend date of this dividend was Friday, October 2nd. Bristol Myers Squibb’s payout ratio is presently 55.88%.

Analyst Ratings Changes

A number of brokerages have issued reports on BMY. JPMorgan Chase & Co. raised their price objective on shares of Bristol Myers Squibb from $67.00 to $73.00 and gave the company an “overweight” rating in a research note on Friday, July 31st. UBS Group cut shares of Bristol Myers Squibb from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 5th. BMO Capital Markets reissued a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, July 27th. Weiss Ratings raised Bristol Myers Squibb from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, August 18th. Finally, Morgan Stanley reduced their price target on Bristol Myers Squibb from $41.00 to $40.00 and set an “underweight” rating on the stock in a research report on Friday, October 30th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, sixteen have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $65.46.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease. The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.